# Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

> **NCT00062387** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 46 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** perifosine

## Key facts

- **NCT ID:** NCT00062387
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-05
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00062387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00062387, "Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00062387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*